Postmenopausal hormone Rx may cut risk for glaucoma

February 1, 2014
Postmenopausal hormone rx may cut risk for glaucoma

(HealthDay)—Use of estrogen-only postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG), according to research published online Jan. 30 in JAMA Ophthalmology.

Paula Anne Newman-Casey, M.D., from University of Michigan in Ann Arbor, and colleagues retrospectively reviewed claims data from 152,163 women 50 years or older enrolled in a U.S. managed-care plan for at least four years and with at least two visits to an eye care provider during the period 2001 through 2009. Outpatient pharmacy claims were used to identify use of PMH medications.

The researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG (hazard ratio [HR], 0.996; P = 0.02), after adjustment for other confounding factors. Each additional month of use of estrogen + progesterone (HR, 0.994; P = 0.08) or + androgen (HR, 0.999; P = 0.89) did not affect risk for POAG.

"If prospective studies confirm the findings of this analysis, novel treatments for this sight-threatening condition may follow," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Study links genes to common forms of glaucoma

April 26, 2012

Results from the largest genetic study of glaucoma, a leading cause of blindness and vision loss worldwide, showed that two genetic variations are associated with primary open angle glaucoma (POAG), a common form of the disease. ...

VTE risk varies by hormone therapy formulation

September 18, 2012

(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin ...

Recommended for you

Study points way forward for retinal disease gene therapy

May 3, 2015

Gene therapy for Leber congenital amaurosis (LCA), an inherited disorder that causes vision loss starting in childhood, improved patients' eyesight and the sensitivity of the retina within weeks of treatment. Both of these ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.